This article is more than 5 years old. Information may no longer be current.
Amgen to collaborate with Simcere to co-develop, commercialize biosimilars in China
Click Here to Manage Email Alerts
Amgen and Simcere Pharmaceutical Group announced a collaboration to co-develop and commercialize four biosimilars in China. The deal includes undisclosed biosimilars in the areas of inflammation and oncology that are already part of Amgen’s existing biosimilars portfolio.
“We are pleased to enter this strategic collaboration with Simcere as we continue to enhance patient access through broader adoption of more competitive therapeutic options worldwide,” Scott Foraker, vice president and general manager of biosimilars at Amgen, said in a company press release. “This agreement brings together Amgen’s long-standing development and biologics manufacturing expertise with Simcere’s local development experience and strong commercial presence in China in the areas of inflammation and oncology.”
The release noted that Amgen will remain responsible for the co-development, marketing approval applications and manufacturing of the biosimilars, while Simcere will be responsible for distribution and commercialization in China. Amgen will also have a limited right to co-promote the products, according to the release.
“This strategic partnership between a world-renowned biotechnology company and a leading Chinese pharma will help to accelerate development and launch of United States and European approved biosimilars in China,” Honggang Feng, president of Simcere, said in the release. “By leveraging our sales network, it will also help to improve the accessibility of high-quality therapeutic antibodies for Chinese patients. This collaboration will allow both companies to further penetrate inflammation and oncology markets in China.”
Reference: